Ha habido 50 transacciones internas recientes registradas para X4 Pharmaceuticals, Inc. (XFOR), incluyendo 34 compras y 12 ventas. El total de compras internas fue valorado en $16.94M y el total de ventas internas en $474.36K.
Internos destacados con actividad reciente incluyen Wyzga Michael S, Stewart Murray, De Craecker Francoise. Las transacciones internas pueden proporcionar información sobre cómo la dirección de la empresa ve la valoración y perspectivas futuras de la acción.
Operaciones de Insiders — XFOR
| Fecha |
Nombre |
Cargo |
Tipo de Transacción |
Acciones |
Precio Promedio |
Valor |
Acciones en Propiedad |
| 2026-01-01 |
Wyzga Michael S |
Director |
Concesión de RSU |
110,000 |
$4.00 |
$440K |
- |
| 2026-01-01 |
Stewart Murray |
Director |
Concesión de RSU |
110,000 |
$4.00 |
$440K |
- |
| 2026-01-01 |
De Craecker Francoise |
Director |
Concesión de RSU |
110,000 |
$4.00 |
$440K |
- |
| 2026-01-01 |
Bridger Gary |
Director |
Concesión de RSU |
110,000 |
$4.00 |
$440K |
- |
| 2025-10-29 |
Kirske David |
Chief Financial Officer |
Concesión de RSU |
1,552,769 |
$1.42 |
$2.2M |
1,552,769 |
| 2025-10-29 |
Craig Adam R |
Executive Chairman |
Concesión de RSU |
2,329,154 |
$1.42 |
$3.31M |
2,329,154 |
| 2025-10-29 |
Volpone John |
President |
Concesión de RSU |
2,329,154 |
$1.42 |
$3.31M |
2,329,154 |
| 2025-10-23 |
Craig Adam R |
Executive Chairman |
Compra Informativa |
86,206 |
$2.90 |
$250K |
376,087 |
| 2025-08-14 |
Kirske David |
Chief Financial Officer |
Concesión de RSU |
193,254 |
- |
- |
193,254 |
| 2025-08-14 |
Craig Adam R |
Executive Chairman |
Concesión de RSU |
289,881 |
- |
- |
289,881 |
| 2025-08-14 |
Volpone John |
President |
Concesión de RSU |
289,881 |
- |
- |
289,881 |
| 2025-08-12 |
Kirske David |
Officer |
Desconocido |
- |
- |
- |
- |
| 2025-08-12 |
Kirske David |
Chief Financial Officer |
Concesión de RSU |
1,073,249 |
$1.42 |
$1.52M |
1,073,249 |
| 2025-08-12 |
Craig Adam R |
Executive Chairman |
Desconocido |
- |
- |
- |
- |
| 2025-08-12 |
Craig Adam R |
Executive Chairman |
Concesión de RSU |
1,609,873 |
$1.42 |
$2.29M |
1,609,873 |
| 2025-08-12 |
Volpone John |
Officer |
Desconocido |
- |
- |
- |
- |
| 2025-08-12 |
Volpone John |
President |
Concesión de RSU |
1,609,873 |
$1.42 |
$2.29M |
1,609,873 |
| 2025-06-09 |
Wyzga Michael S |
Director |
Concesión de RSU |
1,500 |
- |
- |
5,555 |
| 2025-06-09 |
Mcgirr David W J |
Director |
Concesión de RSU |
1,500 |
- |
- |
4,722 |
| 2025-06-09 |
Bridger Gary |
Director |
Concesión de RSU |
1,500 |
- |
- |
4,722 |
| 2025-06-09 |
Stewart Murray |
Director |
Concesión de RSU |
1,500 |
- |
- |
7,883 |
| 2025-06-09 |
De Craecker Francoise |
Director |
Concesión de RSU |
1,500 |
- |
- |
4,722 |
| 2025-06-09 |
Woods Keith |
Director |
Concesión de RSU |
1,500 |
- |
- |
6,000 |
| 2025-05-20 |
Thoren Natasha Fay |
Chief Legal Officer |
Desconocido |
8,166 |
$32.70 |
$267.03K |
- |
| 2025-05-20 |
Thoren Natasha Fay |
Chief Legal Officer |
Concesión de RSU |
3,333 |
- |
- |
9,462 |
| 2025-05-16 |
Baldry Mark |
Chief Commercial Officer |
Compra Informativa |
1,032 |
$2.48 |
$2.56K |
25,337 |
| 2025-05-16 |
Baldry Mark |
Chief Commercial Officer |
Concesión de RSU |
1,032 |
$2.48 |
$2.56K |
25,337 |
| 2025-02-12 |
Baldry Mark |
Chief Commercial Officer |
Concesión de RSU |
600,000 |
- |
- |
729,173 |
| 2025-02-12 |
Mostafa Adam S. |
Chief Financial Officer |
Concesión de RSU |
850,000 |
- |
- |
850,000 |
| 2025-02-12 |
Ragan Paula |
President and CEO |
Concesión de RSU |
2,250,000 |
- |
- |
3,337,386 |
| 2025-02-12 |
Arbet-engels Christophe |
Chief Medical Officer |
Concesión de RSU |
850,000 |
- |
- |
864,207 |
| 2025-02-12 |
Dibiase Mary |
Chief Operating Officer |
Concesión de RSU |
650,000 |
- |
- |
1,140,980 |
| 2025-01-24 |
Baldry Mark |
Chief Commercial Officer |
Venta Informativa |
29,159 |
$0.45 |
$13.24K |
94,123 |
| 2025-01-24 |
Mostafa Adam S. |
Chief Financial Officer |
Venta Informativa |
74,773 |
$0.45 |
$33.95K |
- |
| 2025-01-24 |
Ragan Paula |
President and CEO |
Venta Informativa |
76,473 |
$0.45 |
$34.72K |
1,087,386 |
| 2025-01-24 |
Arbet-engels Christophe |
Chief Medical Officer |
Venta Informativa |
11,624 |
$0.45 |
$5.28K |
14,207 |
| 2025-01-24 |
Dibiase Mary |
Chief Operating Officer |
Venta Informativa |
22,258 |
$0.45 |
$10.09K |
490,980 |
| 2025-01-23 |
Baldry Mark |
Chief Commercial Officer |
Concesión de RSU |
74,773 |
- |
- |
123,282 |
| 2025-01-23 |
Mostafa Adam S. |
Chief Financial Officer |
Concesión de RSU |
74,773 |
- |
- |
74,773 |
| 2025-01-23 |
Ragan Paula |
President and CEO |
Concesión de RSU |
169,940 |
- |
- |
1,163,859 |
| 2025-01-23 |
Arbet-engels Christophe |
Chief Medical Officer |
Concesión de RSU |
25,831 |
- |
- |
25,831 |
| 2025-01-23 |
Dibiase Mary |
Chief Operating Officer |
Concesión de RSU |
61,178 |
- |
- |
513,238 |
| 2024-11-15 |
Baldry Mark |
Chief Commercial Officer |
Compra Informativa |
13,404 |
$0.34 |
$4.6K |
129,173 |
| 2024-11-15 |
Ragan Paula |
President and CEO |
Venta Informativa |
31,897 |
$0.39 |
$12.58K |
993,919 |
| 2024-10-15 |
Ragan Paula |
President and CEO |
Venta Informativa |
31,897 |
$0.56 |
$17.93K |
1,025,816 |
| 2024-10-07 |
Baldry Mark |
Chief Commercial Officer |
Venta Informativa |
11,127 |
$0.58 |
$6.51K |
48,509 |
| 2024-10-07 |
Mostafa Adam S. |
Chief Financial Officer |
Venta Informativa |
230,645 |
$0.55 |
$126.9K |
- |
| 2024-10-07 |
Ragan Paula |
President and CEO |
Venta Informativa |
239,436 |
$0.55 |
$131.52K |
1,057,713 |
| 2024-10-07 |
Taveras Arthur |
Chief Scientific Officer |
Venta Informativa |
76,920 |
$0.56 |
$43.31K |
388,026 |
| 2024-10-07 |
Dibiase Mary |
Chief Operating Officer |
Venta Informativa |
67,695 |
$0.57 |
$38.33K |
452,060 |
■ Informativa — transacción en mercado abierto (más significativa)
■ No informativa (compra) — premio, ejercicio de opción, conversión
■ No informativa (venta) — retención fiscal, venta de adjudicación
■ Neutral — regalo, fideicomiso, vencimiento
